A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
This study is testing a new daily pill called orforglipron to see how well it works and if it is safe compared to a standard insulin injection called insulin glargine. It is designed for adults with type 2 diabetes who also carry extra weight and have a higher risk for heart issues.
You may be able to join if you are an adult with type 2 diabetes who has overweight or obesity and has specific blood sugar levels. People with type 1 diabetes, active liver disease, or certain stomach and pancreas conditions cannot take part.
Over a period of about two years, participants will take either the study pill or the standard insulin and attend up to 27 check-in visits with the study team. Your health, blood sugar, and overall well-being will be closely monitored throughout this time.
This study has been completed and took place at various locations including Daphne, Mobile, and Pelham in Alabama, USA.
- 1Compares a new daily pill with a standard insulin injection
- 2Focuses on adults with type 2 diabetes and extra body weight
- 3Involves regular check-ins over about a two-year period
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.